Your new post is loading...
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies |
Krishan Maggon 's curator insight,
November 13, 2014 7:21 AM
Detailed results of four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014Secukinumab is the first selective interleukin-17A (IL-17A) inhibitor with Phase III data to demonstrate efficacy and improve symptoms in patients with PsA and ASData will include study results from FUTURE 1 and FUTURE 2 in PsA and MEASURE 1 and MEASURE 2 in AS; data to be presented include joint structural damage progression in PsA and symptoms, quality of life/physical function in PsA and ASPsA and AS are part of a family of long-term diseases impacting joints, known as spondyloarthritis (SpA); high unmet treatment need exists for patients living with SpA[1]
Sign up to comment
